FDA Approves Selpercatinib for 3 RET-Positive Cancer Types
The FDA approved the first therapy to treat cancers with rearranged during transfection (RET) gene alterations. (Source: CancerNetwork)
Source: CancerNetwork - May 8, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news
Consuming Antioxidants Through Dietary Intake Beneficial for Patients with Childhood ALL
This study found that the consumption of antioxidants through dietary intake was correlated with reduced rates of infection or mucositis, with no increased risk of relapse or reduced survival. (Source: CancerNetwork)
Source: CancerNetwork - May 8, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
DETECT-A Blood Test Combined with PET-CT May Lead to Surgery with Intent to Cure
In this study, the feasibility and safety of DETECT-A coupled with PET-CT imaging to detect cancer was evaluated using a prospective, interventional study of 10,006 women not previously known to have cancer. (Source: CancerNetwork)
Source: CancerNetwork - May 8, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
Initiation of Adjuvant Therapy Within 3 Weeks After Surgical Resection of GBM Could Be Detrimental
Recent data suggests that, while short delays beyond 5 weeks after surgical resection of glioblastoma did not negatively impact survival outcomes, early initiation of chemoradiation before 3 weeks could be detrimental to patients. (Source: CancerNetwork)
Source: CancerNetwork - May 8, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news
David S. Hong, MD, on Outcomes of Larotrectinib in Patients with TRK Fusion Cancer
The medical oncologist discussed reported outcomes of larotrectinib in patients with TRK fusion cancer by the number of lines of priory therapy or baseline status. (Source: CancerNetwork)
Source: CancerNetwork - May 8, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
FDA Approves Expanded Olaparib Indication to Include Combination with Bevacizumab
The FDA expanded the indication of olaparib to include a combination regimen with bevacizumab for the first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. (Source: CancerNetwork)
Source: CancerNetwork - May 8, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
Decrease in Presentation of High-Risk PSA Levels May Be Associated with Medicaid Expansion
A recent study found that the proportion of men with high-risk prostate-specific antigen levels at diagnosis was decreased in association with Medicaid expansion states. (Source: CancerNetwork)
Source: CancerNetwork - May 7, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news
Patients with Medicaid, No Insurance See Smaller Added Benefits from Experimental Therapies
Given these findings, researchers suggested that a better understanding of the quality of survivorship care that patients with suboptimal insurance receive could help determine how external factors may impact outcomes for these patients. (Source: CancerNetwork)
Source: CancerNetwork - May 7, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
Local Therapy Strategies Appear Effective for Many Patients with Desmoid Tumors
A recent study evaluated the effectiveness of local therapy strategies to treat patients with nonmesenteric desmoid tumors and found that young patients, patients with an extremity location, and patients with large tumors are at higher risk of recurrence. (Source: CancerNetwork)
Source: CancerNetwork - May 7, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news
Study Shows Reduced T-Cell Counts, Functional Exhaustion in Patients with COVID-19
These findings suggest that patients with COVID-19 who do not require intensive care unit admission with total T-cell counts lower than 800/ μL may still require urgent intervention. (Source: CancerNetwork)
Source: CancerNetwork - May 7, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
Cemiplimab Shows Promise for Patients with Advanced Basal Cell Carcinoma
Cemiplimab showed clinically meaningful and durable responses in this group of patients for whom there are no currently approved treatments. (Source: CancerNetwork)
Source: CancerNetwork - May 6, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
CMS Releases New Waivers and Rule Changes for Healthcare Providers Due to COVID-19
The Centers for Medicare& Medicaid Services issued a second interim final rule, which established new regulatory waivers and rule changes to increase flexibility for healthcare providers during the COVID-19 pandemic. (Source: CancerNetwork)
Source: CancerNetwork - May 6, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
Phase III UNITY-CLL Trial Shows Promise for Umbralisib, Ublituximab Combo in CLL
The phase III UNITY-CLL trial evaluating the combination of umbralisib plus ublituximab met its primary endpoint at a prespecified interim analysis and will be stopped early for superior efficacy. (Source: CancerNetwork)
Source: CancerNetwork - May 6, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
FDA Grants Accelerated Approval to Capmatinib for NSCLC
The FDA granted accelerated approval to capmatinib for adult patients with metastatic non-small cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - May 6, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
FDA Grants Orphan Drug Designation to HQP1351 for Chronic Myeloid Leukemia
The FDA granted orphan drug designation to Ascentage Pharma ’s HQP1351 for the treatment of chronic myeloid leukemia. (Source: CancerNetwork)
Source: CancerNetwork - May 5, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
